...
首页> 外文期刊>Vaccine >The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice
【24h】

The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naive recipient mice

机译:TLR3激动剂poly(I:C)靶向CD8 + T细胞,并在过继转移到幼稚受体小鼠中时增强其抗原特异性反应

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

We have recently reported that the toll-like receptor 3 (TLR3) agonist poly(I:C) induces adjuvant effects to post vaccination CD8+ T cells responses through rapid induction of innate mediators, including NK cells, macrophages, dendritic cells (DCs), and inflammatory cytokines. However, whether this TLR3 agonist directly targets CD8+ T cells needs to be carefully investigated. In this study, we found that optimal post vaccination CD8+ T cell responses to ex vivo DC-based vaccination requires triggering of TLR3 signaling pathway in DCs in vitro as well as in the recipient host, indicating a role for other cell types. Real-time PCR analysis revealed that TLRs (TLR1-TLR13) are expressed in purified (>99% pure) CD4+ and CD8+ T cells from C57BL/6 and BALB/c mice, where the magnitude of the expression was strain and cell type dependent. In vitro, treatment of these purified T cells with poly(I:C) modulated the expression of TLRs including TLR3. Furthermore, non-specific and antigen-specific stimulationof CD8+ T cells by phorbol myristate acetate and MHC class I peptide-pulsed splenocytes, respectively, modulated TLR expression in purified CD4+ and CD8+ T cells. Importantly, brief conditioning of purified naive TCR transgenic OT-1 (CD8+) T cells in vitro with poly(I:C) induced activation of these cells in absence of antigen stimulation. Interestingly, when these in vitro poly(I:C)-conditioned OT-1 cells were adoptively transferred into naive recipient followed by peptide vaccination, they showed superior expansion and activation to their naive counterparts. These results suggest that CD8+ T cells can be activated by triggering their TLR3. Furthermore, the data support the notion of direct involvement of TLRs in adaptive immune responses.
机译:最近,我们报道了Toll样受体3(TLR3)激动剂poly(I:C)通过快速诱导先天性介体(包括NK细胞,巨噬细胞,树突状细胞(DC))诱导佐剂作用,从而对疫苗接种后的CD8 + T细胞产生反应,和炎性细胞因子。但是,这种TLR3激动剂是否直接靶向CD8 + T细胞需要仔细研究。在这项研究中,我们发现最佳的疫苗接种后CD8 + T细胞对离体基于DC的疫苗接种的反应需要在DC以及受体宿主中触发TLR3信号通路,这表明其他细胞类型也起作用。实时PCR分析显示TLR(TLR1-TLR13)在来自C57BL / 6和BALB / c小鼠的纯化的CD4 +和CD8 + T细胞中表达(> 99%纯度),其中表达的大小取决于菌株和细胞类型。在体外,用聚(I:C)处理这些纯化的T细胞可调节包括TLR3在内的TLR的表达。此外,佛波肉豆蔻酸酯乙酸盐和MHC I类肽脉冲的脾细胞对CD8 + T细胞的非特异性和抗原特异性刺激分别调节了纯化CD4 +和CD8 + T细胞中的TLR表达。重要的是,在没有抗原刺激的情况下,用聚(I:C)在体外对纯化的天然TCR转基因OT-1(CD8 +)T细胞进行了短暂的条件诱导了这些细胞的活化。有趣的是,当将这些体外聚(I:C)条件化的OT-1细胞过继转移到幼稚受体中,然后进行肽疫苗接种时,它们显示出比其幼稚对应物更好的扩展性和激活性。这些结果表明,CD8 + T细胞可以通过触发其TLR3来激活。此外,数据支持TLR直接参与适应性免疫应答的观点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号